

RECEIVED
CENTRAL FAX CENTER

APR 18 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wu, et al. Confirmation No.: 7123
Serial No.: 10/783,916 Art Unit: 1614
Filed: February 20, 2004 Examiner: Unknown
For: Pyridine, Pyrimidine, Quinoline,
Quinazoline and Naphthalene
Urotensin-II Receptor Antagonists Attorney Docket No.: 017092-0044-999

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:


Enclosed are a *Revocation and Power of Attorney, Change of Correspondence Address* and *Statement under 37 C.F.R. 3.73 (b)* for filing in connection with the above-referenced application. Please update your records accordingly.

The Commissioner is hereby authorized to charge any required fee(s) to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed for such purpose.

Respectfully submitted,

Date: April 18, 2006


Dale L. Rieger 43,045
JONES DAY (Reg. No.)
222 East 41st Street
New York, New York 10017
858.314.1200

Certificate of Facsimile Transmission
I hereby certify that this correspondence is being
facsimile transmitted to the U.S. Patent and Trademark
Office (Fax No. (571) 273-8300) on April 18, 2006
Typed or printed name of person signing this certificate
Dale L. Rieger, Reg. No. 43,045
Signature 

POWER OF ATTORNEY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Wu, et al.

Confirmation No.:

7123 RECEIVED
CENTRAL FAX CENTER

Serial No.: 10/783,916

Art Unit: 1614

APR 18 2006

Filed: February 20, 2004

Examiner: Unknown

For: Pyridine, Pyrimidine, Quinoline, Quinazoline
and Naphthalene Urotensin-II Receptor
Antagonists

Attorney Docket No.: 017092-0044-999

REVOCATION AND POWER OF ATTORNEYCommissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Encysive Pharmaceuticals, Inc. (applicant or assignee) hereby revokes any and all previous powers and appoints:

☒ Practitioners at Customer Number 20583

as his/her/its/their attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please direct all correspondence address for the above-identified application to:

☒ The above mentioned Customer Number.☒ Firm or Individual Name:Address: Jones Day, 222 East 41st Street, New York, New York 10017

Telephone: (212) 901-9028

I am the:

☐

Applicant/Inventor

☒

Assignee of record of the entire interest. See 37 CFR 3.71.

(Statement under 37 CFR 3.73(b) is applicable)

SIGNATURE of Applicant or Assignee of Record			
Date:	2-16-2006	Signature:	<i>Paul S. Manning</i>
		Typed Name:	
		Position/Title:	Vice President & General Counsel

Statement Under 37 C.F.R. 3.73(b)

Encysive Pharmaceuticals, Inc. states that it is:

☒

the assignee of the entire right, title, and interest; or

☐

an assignee of less than the entire right, title and interest.

The extent (by, percentage) of its ownership interest is %

in the patent application/patent identified above by virtue of either:

- ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office on May 24, 2004 at Reel 015359, Frame 0356, or for which a copy thereof is attached.

OR

- ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: To:
The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached.

2. From: To:
The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached.

3. From: To:
The document was recorded in the United States Patent and Trademark Office on at Reel , Frame , or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☐ Copies of assignments or other documents in the chain of title are attached.
[Note: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: Encysive Pharmaceuticals, Inc.

Date:	2-16-2006	Signature:	<i>Paul S. Manning</i>
		Typed Name:	
		Position/Title:	Vice President & General Counsel

Note: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required.

- ☐ Total of forms are submitted.

PTO/SB/122 (01-06)

Approved for use through 12/31/2008. DMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**CHANGE OF
CORRESPONDENCE ADDRESS
Application**Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Application Number	10/783,916
Filing Date	February 20, 2004
First Named Inventor	Chengde Wu
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	017092-0044-999

**RECEIVED
CENTRAL FAX CENTER****APR 18 2006**

Please change the Correspondence Address for the above-identified patent application to:

☒ The address associated with
Customer Number:

20583

OR

☐ Firm or
Individual Name

Address

City

State

Zip

Country

Telephone

Email

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).

I am the:

☐ Applicant/Inventor☒ Assignee of record of the entire interest.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).☐ Attorney or agent of record. Registration Number _____☐ Registered practitioner named in the application transmittal letter in an application without an executed oath or declaration. See 37 CFR 1.33(a)(1). Registration Number _____

Signature

Typed or Printed
Name

Date

2-16-2006

Telephone

(713) 578-6435

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ *Total of _____ forms are submitted.

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/86 (12-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Wu, et al.Application No./Patent No./Control No.: 10/783,916Filed/Issue Date: February 20, 2004Entitled: Pyridine, Pyrimidine, Quinoline, Quinazoline and Naphthalene Urotensin-II Receptor AntagonistsEncysive Pharmaceuticals, Inc.a Corporation

(Name of Assignee)

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 015359, Frame 0358, or a true copy of the original assignment is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Paul S. Manierre
Signature
Paul S. Manierre
Printed or Typed Name
Vice President & General Counsel
Title

Date

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.